lucidenic acid a profile

lucidenic acid A: isolated from fruiting bodies of Ganoderma lucidum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	14109375
CHEMBL ID	460969
CHEBI ID	172690
SCHEMBL ID	6522668
MeSH ID	M0460227

Synonym
lucidenic acid a
(4r)-4-[(5r,7s,10s,13r,14r,17r)-7-hydroxy-4,4,10,13,14-pentamethyl-3,11,15-trioxo-1,2,5,6,7,12,16,17-octahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid
CHEBI:172690
CHEMBL460969
bdbm50356926
7beta-hydroxy-4,4,14alpha-trimethyl-3,11,15-trioxo-5alpha-chol-8-en-24-oic acid
SCHEMBL6522668
AC-34115
95311-94-7
AKOS037515140
lucidenicacida
CS-0027808
HY-N6862
lucideric acid a
D85042
MS-28395
DTXSID401316662

Class	Description
triterpenoid	Any terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cholinesterase	Homo sapiens (human)	IC50 (µMol)	200.0000	0.0000	1.5599	10.0000	AID630340
Acetylcholinesterase	Homo sapiens (human)	IC50 (µMol)	24.0400	0.0000	0.9332	10.0000	AID630339
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	Cholinesterase	Homo sapiens (human)
learning	Cholinesterase	Homo sapiens (human)
negative regulation of cell population proliferation	Cholinesterase	Homo sapiens (human)
neuroblast differentiation	Cholinesterase	Homo sapiens (human)
peptide hormone processing	Cholinesterase	Homo sapiens (human)
response to alkaloid	Cholinesterase	Homo sapiens (human)
cocaine metabolic process	Cholinesterase	Homo sapiens (human)
negative regulation of synaptic transmission	Cholinesterase	Homo sapiens (human)
response to glucocorticoid	Cholinesterase	Homo sapiens (human)
response to folic acid	Cholinesterase	Homo sapiens (human)
choline metabolic process	Cholinesterase	Homo sapiens (human)
acetylcholine catabolic process	Cholinesterase	Homo sapiens (human)
acetylcholine catabolic process in synaptic cleft	Acetylcholinesterase	Homo sapiens (human)
regulation of receptor recycling	Acetylcholinesterase	Homo sapiens (human)
osteoblast development	Acetylcholinesterase	Homo sapiens (human)
acetylcholine catabolic process	Acetylcholinesterase	Homo sapiens (human)
cell adhesion	Acetylcholinesterase	Homo sapiens (human)
nervous system development	Acetylcholinesterase	Homo sapiens (human)
synapse assembly	Acetylcholinesterase	Homo sapiens (human)
receptor internalization	Acetylcholinesterase	Homo sapiens (human)
negative regulation of synaptic transmission, cholinergic	Acetylcholinesterase	Homo sapiens (human)
amyloid precursor protein metabolic process	Acetylcholinesterase	Homo sapiens (human)
positive regulation of protein secretion	Acetylcholinesterase	Homo sapiens (human)
retina development in camera-type eye	Acetylcholinesterase	Homo sapiens (human)
acetylcholine receptor signaling pathway	Acetylcholinesterase	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Acetylcholinesterase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
amyloid-beta binding	Cholinesterase	Homo sapiens (human)
catalytic activity	Cholinesterase	Homo sapiens (human)
acetylcholinesterase activity	Cholinesterase	Homo sapiens (human)
cholinesterase activity	Cholinesterase	Homo sapiens (human)
protein binding	Cholinesterase	Homo sapiens (human)
hydrolase activity, acting on ester bonds	Cholinesterase	Homo sapiens (human)
enzyme binding	Cholinesterase	Homo sapiens (human)
choline binding	Cholinesterase	Homo sapiens (human)
identical protein binding	Cholinesterase	Homo sapiens (human)
amyloid-beta binding	Acetylcholinesterase	Homo sapiens (human)
acetylcholinesterase activity	Acetylcholinesterase	Homo sapiens (human)
cholinesterase activity	Acetylcholinesterase	Homo sapiens (human)
protein binding	Acetylcholinesterase	Homo sapiens (human)
collagen binding	Acetylcholinesterase	Homo sapiens (human)
hydrolase activity	Acetylcholinesterase	Homo sapiens (human)
serine hydrolase activity	Acetylcholinesterase	Homo sapiens (human)
acetylcholine binding	Acetylcholinesterase	Homo sapiens (human)
protein homodimerization activity	Acetylcholinesterase	Homo sapiens (human)
laminin binding	Acetylcholinesterase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular region	Cholinesterase	Homo sapiens (human)
nuclear envelope lumen	Cholinesterase	Homo sapiens (human)
endoplasmic reticulum lumen	Cholinesterase	Homo sapiens (human)
blood microparticle	Cholinesterase	Homo sapiens (human)
plasma membrane	Cholinesterase	Homo sapiens (human)
extracellular space	Cholinesterase	Homo sapiens (human)
extracellular region	Acetylcholinesterase	Homo sapiens (human)
basement membrane	Acetylcholinesterase	Homo sapiens (human)
extracellular space	Acetylcholinesterase	Homo sapiens (human)
nucleus	Acetylcholinesterase	Homo sapiens (human)
Golgi apparatus	Acetylcholinesterase	Homo sapiens (human)
plasma membrane	Acetylcholinesterase	Homo sapiens (human)
cell surface	Acetylcholinesterase	Homo sapiens (human)
membrane	Acetylcholinesterase	Homo sapiens (human)
neuromuscular junction	Acetylcholinesterase	Homo sapiens (human)
synaptic cleft	Acetylcholinesterase	Homo sapiens (human)
synapse	Acetylcholinesterase	Homo sapiens (human)
perinuclear region of cytoplasm	Acetylcholinesterase	Homo sapiens (human)
side of membrane	Acetylcholinesterase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay ID	Title	Year	Journal	Article
AID711441	Cytotoxicity against human HeLa cells	2012	Journal of natural products, Nov-26, Volume: 75, Issue:11	Lanostanoids from fungi: a group of potential anticancer compounds.
AID355401	Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio by trypan blue staining method	2003	Journal of natural products, Dec, Volume: 66, Issue:12	Lucidenic acids P and Q, methyl lucidenate P, and other triterpenoids from the fungus Ganoderma lucidum and their inhibitory effects on Epstein-Barr virus activation.
AID357593	Cytotoxicity against human HepG2 cells	2001	Journal of natural products, Aug, Volume: 64, Issue:8	Cytotoxicity of Ganoderma lucidum triterpenes.
AID355403	Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA induction at 500 molar ratio relative to 12-O-tetradecanoylphorbol-13-acetate by immunofluorescence technique	2003	Journal of natural products, Dec, Volume: 66, Issue:12	Lucidenic acids P and Q, methyl lucidenate P, and other triterpenoids from the fungus Ganoderma lucidum and their inhibitory effects on Epstein-Barr virus activation.
AID357594	Cytotoxicity against human HepG2(2.2.15) cells	2001	Journal of natural products, Aug, Volume: 64, Issue:8	Cytotoxicity of Ganoderma lucidum triterpenes.
AID355402	Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA induction at 1000 molar ratio relative to 12-O-tetradecanoylphorbol-13-acetate by immunofluorescence technique	2003	Journal of natural products, Dec, Volume: 66, Issue:12	Lucidenic acids P and Q, methyl lucidenate P, and other triterpenoids from the fungus Ganoderma lucidum and their inhibitory effects on Epstein-Barr virus activation.
AID355404	Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA induction at 100 molar ratio relative to 12-O-tetradecanoylphorbol-13-acetate by immunofluorescence technique	2003	Journal of natural products, Dec, Volume: 66, Issue:12	Lucidenic acids P and Q, methyl lucidenate P, and other triterpenoids from the fungus Ganoderma lucidum and their inhibitory effects on Epstein-Barr virus activation.
AID630340	Inhibition of BChE assessed as hydrolysis of butrylcholine preincubated for 15 mins measured after 15 mins by colorimetric Ellman assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Selective cholinesterase inhibition by lanostane triterpenes from fruiting bodies of Ganoderma lucidum.
AID357597	Cytotoxicity against mouse P388 cells	2001	Journal of natural products, Aug, Volume: 64, Issue:8	Cytotoxicity of Ganoderma lucidum triterpenes.
AID357596	Cytotoxicity against human CCM2 cells	2001	Journal of natural products, Aug, Volume: 64, Issue:8	Cytotoxicity of Ganoderma lucidum triterpenes.
AID355406	Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed per 32 pmol TPA by immunofluorescence technique	2003	Journal of natural products, Dec, Volume: 66, Issue:12	Lucidenic acids P and Q, methyl lucidenate P, and other triterpenoids from the fungus Ganoderma lucidum and their inhibitory effects on Epstein-Barr virus activation.
AID357595	Cytotoxicity against human KB cells	2001	Journal of natural products, Aug, Volume: 64, Issue:8	Cytotoxicity of Ganoderma lucidum triterpenes.
AID355405	Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA induction at 10 molar ratio relative to 12-O-tetradecanoylphorbol-13-acetate by immunofluorescence technique	2003	Journal of natural products, Dec, Volume: 66, Issue:12	Lucidenic acids P and Q, methyl lucidenate P, and other triterpenoids from the fungus Ganoderma lucidum and their inhibitory effects on Epstein-Barr virus activation.
AID630339	Inhibition of AChE assessed as hydrolysis of acetylcholine preincubated for 15 mins measured after 15 mins by colorimetric Ellman assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Selective cholinesterase inhibition by lanostane triterpenes from fruiting bodies of Ganoderma lucidum.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (50.00)	29.6817
2010's	3 (37.50)	24.3611
2020's	1 (12.50)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (12.50%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (87.50%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
Berberine chloride (TN) [no description available]	2.06	1	organic molecular entity
tetradecanoylphorbol acetate Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.	2.03	1	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
etoposide [no description available]	3.17	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
eburicoic acid eburicoic acid: structure	3.17	1
10-hydroxycamptothecin [no description available]	3.17	1	pyranoindolizinoquinoline
lanosterol [no description available]	2	1	14alpha-methyl steroid; 3beta-sterol; tetracyclic triterpenoid	bacterial metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
ganoderic acid a [no description available]	3.17	1	triterpenoid
ganoderiol f ganoderiol F: a ganoderma triterpene from Ganoderma amboinense; structure in first source	3.57	2	triterpenoid
Ganodermanontriol [no description available]	3.57	2	triterpenoid	metabolite
beta carotene beta Carotene: A carotenoid that is a precursor of VITAMIN A. Beta carotene is administered to reduce the severity of photosensitivity reactions in patients with erythropoietic protoporphyria (PORPHYRIA, ERYTHROPOIETIC).. provitamin A : A provitamin that can be converted into vitamin A by enzymes from animal tissues.	2.01	1	carotenoid beta-end derivative; cyclic carotene	antioxidant; biological pigment; cofactor; ferroptosis inhibitor; human metabolite; mouse metabolite; plant metabolite; provitamin A
poricoic acid g poricoic acid G: from Poria cocos (Polyporaceae); structure in first source. poricoic acid G : A tricyclic triterpenoid isolated from Poria cocos.	3.17	1	dicarboxylic acid; secondary alcohol; tricyclic triterpenoid	fungal metabolite
polyporenic acid c [no description available]	3.17	1
trametenolic acid b trametenolic acid B: from Trametes lactinea; structure in first source	3.17	1	triterpenoid
ganodermadiol ganodermadiol: isolated from Ganoderma lucidum; structure given in first source. ganoderol B : A tetracyclic triterpenoid that is lanosta-7,9(11),24-triene which is substituted by hydroxy groups at positions 3 and 27. It has been isolated from several Ganoderma species.	3.57	2	3beta-sterol; primary allylic alcohol; tetracyclic triterpenoid	antiviral agent; fungal metabolite; hepatoprotective agent
lucidenic acid n lucidenic acid N: from the dried fruiting bodies of Ganoderma lucidum (polyporaceae); structure in first source. lucidenic acid N : A tetracyclic triterpenoid that is 25,26,27-trinorlanost-8-en-24-oic acid substituted by hydroxy groups at positions 3 and 7 and oxo groups at positions 11 and 15 respectively (the 3beta,5alpha,7beta stereoisomer). Isolated from the fruiting bodies of Ganoderma lucidum, it exhibits cytotoxicity against tumour cells.	2.72	3	cyclic terpene ketone; dioxo monocarboxylic acid; secondary alcohol; tetracyclic triterpenoid	antineoplastic agent; EC 3.1.1.8 (cholinesterase) inhibitor; metabolite
methyl lucidenate f methyl lucidenate F: from the dried fruiting bodies of Ganoderma lucidum (polyporaceae); structure in first source	2.01	1	triterpenoid
ganoderic acid t ganoderic acid T: down-regulates expression of both MMP-2 and MMP-9; isolated from Ganoderma lucidum; structure in first source	3.17	1
ganoderic acid f ganoderic acid F: isolated from Ganoderma lucidum; structure in first source	3.54	2	triterpenoid
inotodiol inotodiol: structure in first source	3.17	1
3,7-dioxolanosta-8,24-dien-26-oic acid [no description available]	3.17	1
ganoderic acid c2 ganoderic acid C2: from the fruiting body of Ganoderma; structure in first source	3.17	1	triterpenoid
ganoderic acid y ganoderic acid Y: has antiviral activity; isolated from Ganoderma lucidum; structure in first source	3.57	2	triterpenoid
7-oxo-ganoderic acid z 7-oxo-ganoderic acid Z: from the mushroom Ganoderma lucidum; structure in first source	3.17	1

Condition	Relationship Strength	Studies
B-Cell Lymphoma [description not available]	2.01	1
Lymphoma, B-Cell A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.	2.01	1
2019 Novel Coronavirus Disease [description not available]	2.41	1
Hepatocellular Carcinoma [description not available]	2.03	1
Cancer of Liver [description not available]	2.03	1
Invasiveness, Neoplasm [description not available]	2.03	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.03	1
Liver Neoplasms Tumors or cancer of the LIVER.	2.03	1

lucidenic acid a

Description

Cross-References

Synonyms (17)

Drug Classes (1)

Protein Targets (2)

Inhibition Measurements

Biological Processes (25)

Molecular Functions (15)

Ceullar Components (16)

Bioassays (14)

Research

Studies (8)

Market Indicators

Research Demand Index: 12.36

Study Types

lucidenic acid a

Description

Cross-References

Synonyms (17)

Drug Classes (1)

Protein Targets (2)

Inhibition Measurements

Biological Processes (25)

Molecular Functions (15)

Ceullar Components (16)

Bioassays (14)

Research

Studies (8)

Market Indicators

Research Demand Index: 12.36

Study Types

Related Drugs (23)

Related Conditions (8)